GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Liquidia Corp (NAS:LQDA) » Definitions » Beneish M-Score
中文

Liquidia (Liquidia) Beneish M-Score

: -3.89 (As of Today)
View and export this data going back to 2018. Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.89 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Liquidia's Beneish M-Score or its related term are showing as below:

LQDA' s Beneish M-Score Range Over the Past 10 Years
Min: -5.86   Med: -2.2   Max: 12.24
Current: -3.89

During the past 8 years, the highest Beneish M-Score of Liquidia was 12.24. The lowest was -5.86. And the median was -2.20.


Liquidia Beneish M-Score Historical Data

The historical data trend for Liquidia's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Liquidia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial -1.86 10.47 12.24 -2.54 -3.89

Liquidia Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.54 -2.35 -3.17 -3.16 -3.89

Competitive Comparison

For the Biotechnology subindustry, Liquidia's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Liquidia Beneish M-Score Distribution

For the Biotechnology industry and Healthcare sector, Liquidia's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Liquidia's Beneish M-Score falls into.



Liquidia Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Liquidia for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7376+0.528 * 0.9829+0.404 * 1.05+0.892 * 1.0975+0.115 * 1.4145
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.2579+4.679 * -0.292626-0.327 * 0.7095
=-3.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $4.06 Mil.
Revenue was 4.531 + 3.678 + 4.786 + 4.493 = $17.49 Mil.
Gross Profit was 3.538 + 3.108 + 4.115 + 3.839 = $14.60 Mil.
Total Current Assets was $89.90 Mil.
Total Assets was $118.33 Mil.
Property, Plant and Equipment(Net PPE) was $6.18 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.18 Mil.
Selling, General, & Admin. Expense(SGA) was $44.74 Mil.
Total Current Liabilities was $18.55 Mil.
Long-Term Debt & Capital Lease Obligation was $2.36 Mil.
Net Income was -27.45 + -15.79 + -23.517 + -11.745 = $-78.50 Mil.
Non Operating Income was 0 + 0 + 0 + -2.311 = $-2.31 Mil.
Cash Flow from Operations was -15.982 + -11.561 + -5.564 + -8.457 = $-41.56 Mil.
Total Receivables was $5.02 Mil.
Revenue was 5.36 + 3.165 + 3.918 + 3.492 = $15.94 Mil.
Gross Profit was 4.666 + 2.425 + 3.187 + 2.798 = $13.08 Mil.
Total Current Assets was $99.81 Mil.
Total Assets was $129.20 Mil.
Property, Plant and Equipment(Net PPE) was $6.25 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.65 Mil.
Selling, General, & Admin. Expense(SGA) was $32.41 Mil.
Total Current Liabilities was $8.80 Mil.
Long-Term Debt & Capital Lease Obligation was $23.38 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(4.061 / 17.488) / (5.017 / 15.935)
=0.232216 / 0.314842
=0.7376

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(13.076 / 15.935) / (14.6 / 17.488)
=0.820584 / 0.834858
=0.9829

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (89.899 + 6.184) / 118.332) / (1 - (99.811 + 6.252) / 129.198)
=0.188022 / 0.179066
=1.05

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=17.488 / 15.935
=1.0975

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(3.647 / (3.647 + 6.252)) / (2.178 / (2.178 + 6.184))
=0.368421 / 0.260464
=1.4145

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(44.742 / 17.488) / (32.411 / 15.935)
=2.55844 / 2.03395
=1.2579

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2.364 + 18.55) / 118.332) / ((23.382 + 8.8) / 129.198)
=0.17674 / 0.249091
=0.7095

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-78.502 - -2.311 - -41.564) / 118.332
=-0.292626

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Liquidia has a M-score of -3.89 suggests that the company is unlikely to be a manipulator.


Liquidia Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Liquidia's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Liquidia (Liquidia) Business Description

Traded in Other Exchanges
Address
419 Davis Drive, Suite 100, Morrisville, NC, USA, 27560
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH). It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension.
Executives
Rajeev Saggar officer: Chief Medical Officer 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Jason Adair officer: V.P. Crp Dvlpmnt and Strtgy C/O LIQUIDIA TECHNOLOGIES, INC., 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Paul B Manning director, 10 percent owner 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Roger Jeffs director
Caligan Partners Lp director, 10 percent owner, other: See Remarks 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Robert A Lippe officer: Chief Operations Officer C/O ALEXZA PHARMACEUTICALS, INC., 2091 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Scott Moomaw officer: SVP, Commercial P.O. BOX 110085, RESEARCH TRIANGLE PARK NC 27709
Michael Kaseta officer: Chief Financial Officer 7100 WEST CREDIT AVENUE, SUITE 101, MISSISSAUGA A6 L5N OE4
Russell Schundler officer: General Counsel P.O. BOX 110085, RESEARCH TRIANGLE PARK NC 27709
Arthur S Kirsch director 7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
David Edward Johnson 10 percent owner 590 MADISON AVENUE, NEW YORK NY 10022
Katherine Rielly-gauvin director 419 DAVIS DRIVE, MORRISVILLE NC 27560
Raman Singh director C/O LIQUIDIA TECHNOLOGIES, INC., 419 DAVIS DRIVE, SUITE 100, MORRISVILLE NC 27560
Joanna Horobin director 215 FIRST STREET, SUITE 440, CAMBRIDGE MA 02142
Stephen M Bloch director 285 RIVERSIDE AVENUE, SUITE 250, WESTPORT CT 06880